On Nov. 30, 2020, Jaguar Health subsidiary, Napo Pharmaceuticals, announced that Jaguar and Napo are planning to develop and commercialize crofelemer, the Company’s novel proprietary drug, for an indication of prophylaxis and/or symptomatic relief of inflammatory diarrhea, initially to be studied in a ﾑlong-hauler’ COVID-19 recovery patient population in Europe.